229 related articles for article (PubMed ID: 25821636)
1. Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine.
Coyne CP; Jones T; Bear R
J Cancer Ther; 2015 Jan; 6(1):62-89. PubMed ID: 25821636
[TBL] [Abstract][Full Text] [Related]
2. Anti-Neoplastic Cytotoxicity of Gemcitabine-(C
Coyne CP; Jones T; Bear R
J Cancer Res Ther Oncol; 2014 Apr; 2(1):. PubMed ID: 25844392
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-(C
Coyne CP; Jones T; Bear R
J Clin Exp Oncol; 2013; 2(2):. PubMed ID: 26251840
[TBL] [Abstract][Full Text] [Related]
4. Anti-Neoplastic Cytotoxicity of Gemcitabine-(C
Coyne CP; Jones T; Bear R
Med Chem (Los Angeles); 2013 May; 3(2):210-223. PubMed ID: 26225219
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of Gemcitabine-(C
Coyne CP; Jones T; Bear R
J Cancer Ther; 2012 Oct; 3(5A):689-711. PubMed ID: 26225216
[TBL] [Abstract][Full Text] [Related]
6. Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C
Coyne CP; Jones T; Bear R
Cancer Clin Oncol; 2012 Nov; 1(2):49-80. PubMed ID: 26225190
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma.
Coyne CP; Jones T; Pharr T
Bioorg Med Chem; 2011 Jan; 19(1):67-76. PubMed ID: 21169024
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate.
Coyne CP; Jones T; Bear R
Cancer Biother Radiopharm; 2012 Feb; 27(1):41-55. PubMed ID: 22191802
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin-[Anti-HER2/
Coyne CP; Jones T; Sygula A; Bailey J; Pinchuk L
J Cancer Ther; 2011 Mar; 2(1):22-39. PubMed ID: 26229727
[TBL] [Abstract][Full Text] [Related]
10. Carnosic Acid, Tangeretin, and Ginkgolide-B Anti-neoplastic Cytotoxicity in Dual Combination with Dexamethasone-[anti-EGFR] in Pulmonary Adenocarcinoma (A549).
Coyne CP; Narayanan L
Anticancer Agents Med Chem; 2019; 19(6):802-819. PubMed ID: 30514195
[TBL] [Abstract][Full Text] [Related]
11. Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen.
Coyne CP; Narayanan L
Curr Pharm Des; 2018; 24(11):1224-1240. PubMed ID: 29141539
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549).
Coyne CP; Narayanan L
Chem Biol Drug Des; 2017 Mar; 89(3):379-399. PubMed ID: 27561602
[TBL] [Abstract][Full Text] [Related]
13. Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition.
Coyne CP; Ross MK; Bailey JG
J Drug Target; 2009 Jul; 17(6):474-89. PubMed ID: 19480561
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine- (C
Coyne CP; Narayanan L
J Pharm Drug Deliv Res; 2015; 4(1):. PubMed ID: 26613088
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549).
Coyne CP; Narayanan L
Drug Des Devel Ther; 2016; 10():2575-97. PubMed ID: 27574398
[TBL] [Abstract][Full Text] [Related]
16. Mebendazole in simultaneous combination with dexamethasone-(C
Coyne CP; Narayanan L
J Exp Ther Oncol; 2019 Dec; 13(2):81-118. PubMed ID: 31881126
[TBL] [Abstract][Full Text] [Related]
17. A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor.
Rosenblum MG; Horn SA; Cheung LH
Int J Cancer; 2000 Oct; 88(2):267-73. PubMed ID: 11004679
[TBL] [Abstract][Full Text] [Related]
18. Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors.
Wu SC; Chen YJ; Wang HC; Chou MY; Chang TY; Yuan SS; Chen CY; Hou MF; Hsu JT; Wang YM
Theranostics; 2016; 6(1):118-30. PubMed ID: 26722378
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").
Fukutome M; Maebayashi K; Nasu S; Seki K; Mitsuhashi N
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):528-36. PubMed ID: 16965995
[TBL] [Abstract][Full Text] [Related]
20. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]